Inhibited CSF1R Alleviates Ischemia Injury via Inhibition of Microglia M1 Polarization and NLRP3 Pathway

Figure 7

Illustrative mechanism for Ki20227 administration to alleviate the ischemic injury. Ki20227 treatment as CSF1R inhibitor could inhibit microglia number and improve behavioral deficits and attenuate microglia-related inflammation, which is verified by a reduction in both microglia M1 phenotype activation and Iba1 expression, meanwhile, increase of microglia M2 phenotype expression. The downregulation of the NLRP3 pathways and inflammasome activation involved the neuroprotective mechanism of CSF1R inhibitor in ischemia stroke.